Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Trevi Therapeutics (TRVI) has drawn investor attention after a recent move in its share price, with the stock closing at $11.92 and showing mixed returns over the past week, month, and past three months. See our latest analysis for Trevi Therapeutics. That 12.03% 7 day share price return and 13.42% 30 day share price return sit against a slightly negative 90 day share price return. At the same time, the 1 year total shareholder return of 163.72% and very large 5 year total shareholder return suggest earlier investors have already seen significant upside. This may indicate that recent moves reflect shifting expectations for Trevi Therapeutics' development pipeline and risk profile rather than a new trend on their own. If Trevi's recent swings have you thinking about what else could be setting up for future growth, take a look at our screener of 27 healthcare AI stocks as
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Participate in Upcoming March ConferencesGlobeNewswire
- Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswire
- Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)PR Newswire
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- TRVI's page on the SEC website